Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor ...
Qurient announced the first patient dosed in a Phase 2 study of mocaciclib (Q901) for CDK4/6 inhibitor-resistant HR+ breast ...
Abemaciclib significantly prolonged PFS compared with placebo for patients with advanced dedifferentiated liposarcoma, ...
Dedifferentiated liposarcoma (DDLS) is a rare and aggressive soft tissue cancer with few effective treatment options. But now ...
Pharmaceutical Technology on MSN
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo
AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...
Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive ...
AstraZeneca (AZN) stock is in focus as the FDA delays review of a breast cancer therapy containing its next-gen oral SERD ...
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen ...
QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results